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MAIN POINTS:  47 
• Resident microglia in MFP2 deficient mice exhibit a proliferative and immunologically activated 48 
state but they lack signs of phagocytic and neurotoxic activity 49 
• The chronically reactive microglia lose their typical homeostatic markers but upregulate 50 
pathways associated with growth and proliferation 51 
• The molecular signature of microglia in Mfp2
-/- 
brain strongly diverges from microglia in the 52 
neurodegenerative milieu of an ALS mouse model  53 
 54 
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ABSTRACT 58 
The functional diversity and molecular adaptations of reactive microglia in the chronically inflamed 59 
central nervous system (CNS) are poorly understood. We previously showed that mice lacking 60 
multifunctional protein 2 (MFP2), a pivotal enzyme in peroxisomal β-oxidation, persistently accumulate 61 
reactive myeloid cells in the gray matter of the CNS. Here we show that the increased numbers of 62 
myeloid cells solely derive from proliferation of resident microglia and not from infiltrating monocytes. 63 
We defined the signature of Mfp2
-/-
 microglia by gene expression profiling after acute isolation, which 64 
was validated by quantitative PCR, immunohistochemical and flow cytometric analysis. The features 65 
of Mfp2
-/-
 microglia were compared with those from SOD1
G93A
 mice, an amyotrophic lateral sclerosis 66 
model.  In contrast to the neurodegenerative milieu of SOD1
G93A
 spinal cord, neurons were intact in 67 
Mfp2
-/-
 brain and Mfp2
-/-
 microglia lacked signs of phagocytic and neurotoxic activity. The chronically 68 
reactive state of Mfp2
-/-
 microglia was accompanied by downregulation of markers that specify the 69 
unique microglial signature in homeostatic conditions. In contrast, mammalian target of rapamycin 70 
(mTOR) and downstream glycolytic and protein translation pathways were induced, indicative of 71 
metabolic adaptations. Mfp2
-/-
 microglia were immunologically activated but not polarized to a pro- or 72 
anti-inflammatory phenotype. A peripheral lipopolysaccharide challenge provoked an exaggerated 73 
inflammatory response in Mfp2
-/-
 brain, consistent with a primed state. Taken together, we 74 
demonstrate that chronic activation of resident microglia does not necessarily lead to phagocytosis nor 75 
overt neurotoxicity. 76 
 77 
 78 
 79 
  80 
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INTRODUCTION 81 
Microglia, the resident immune cells of the CNS, are actively engaged in both homeostasis and 82 
pathology in the adult brain. Under physiological conditions, microglia constantly survey the 83 
microenvironment and communicate in a bidirectional way with neural cells (Ransohoff and Perry, 84 
2009, Hughes, 2012, Gomez-Nicola et al., 2013, Prinz and Priller, 2014). It has become clear that 85 
microglia play a critical role in neuronal plasticity by controlling synaptic function and synaptogenesis 86 
(Tremblay et al., 2010, Salter and Beggs, 2014). Recently, important progress was made in the 87 
molecular characterization of homeostatic microglia, by differentiating their transcriptome signature 88 
from that of neural cells and other myeloid cells (Butovsky et al., 2012, Gautier et al., 2012, Chiu et al., 89 
2013, Hickman et al., 2013, Butovsky et al., 2014).  90 
In addition to their role in CNS homeostasis, microglia sense CNS damage and can act as versatile 91 
effector cells during neuropathological conditions. To this end, microglia adopt a range of activation 92 
states which remain ill-defined at the molecular level. In particular, the diverse phenotypes of microglia 93 
in conditions of chronic stress in the brain are poorly understood (Gomez-Nicola et al., 2013, Cherry et 94 
al., 2014). The morphological transition from ramified to amoeboid is accompanied by new effector 95 
functions that can vary widely and encompass proliferation, migration, production of cytokines and 96 
chemokines, and phagocytic activity. Whether chronically activated microglia always attain neurotoxic 97 
properties is still a matter of debate (Biber et al., 2014). An undervalued aspect in chronic 98 
neuroinflammation is that concomitant with acquiring novel shapes and functions, microglia might also 99 
lose features related to their homeostatic role. To better understand the spectrum of phenotypes of 100 
reactive microglia, information on gene expression and insights in signaling pathways are necessary. 101 
Recently, the microglia transcriptome  of SOD1
G93A
 mice, an amyotrophic lateral sclerosis (ALS) model 102 
was defined (Butovsky et al., 2012, Chiu et al., 2013). These microglia concurrently upregulate both 103 
neurotoxic and neuroprotective factors as well as genes associated with lysosomal activity and 104 
phagocytosis (Chiu et al., 2013). Their molecular profile was different from that of lipopolysaccharide 105 
(LPS)-activated microglia and of M1 or M2 macrophages, and was denoted as a neurodegeneration-106 
specific signature (Chiu et al., 2013). 107 
Chronic microglia activation is an important hallmark of many neurodegenerative diseases and 108 
contributes significantly to the progression of these disorders (Glass et al., 2010). Moreover, microglial 109 
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dysfunction might underlie some neurological disorders, such as Rett’s syndrome (Derecki et al., 110 
2013) and Nasu-Hakola disease (Satoh et al., 2011). Also in X-linked adrenoleukodystrophy, a 111 
neurometabolic disorder caused by peroxisomal β-oxidation deficiency (Kemp et al., 2012), microglia 112 
seem to play a pivotal role in disease pathogenesis. This is inferred from the therapeutic efficacy of 113 
bone marrow transplantation or hematopoietic stem cell gene therapy to halt the inflammatory 114 
demyelination seen in the cerebral childhood form of the disease (ccALD) (Cartier et al., 2009, Cartier 115 
and Aubourg, 2010).  Due to the absence of neuroinflammation in the corresponding mouse model 116 
(Abcd1
-/-
), the precise molecular abnormalities leading to cerebral inflammation and/or microglial 117 
dysfunction cannot be investigated (Kemp et al., 2012). Interestingly, we recently showed that mice 118 
lacking multifunctional protein-2 (MFP2; also known as D-bifunctional protein), a peroxisomal β-119 
oxidation enzyme downstream of the ABCD1 transporter, develop robust neuroinflammation (Huyghe 120 
et al., 2006c, Verheijden et al., 2013). This initiates before the age of 8 weeks and is confined to the 121 
gray matter throughout the brain and spinal cord. The expanding inflammation parallels the 122 
aggravating neurological phenotype of the mice, characterized by motor and cognitive impairments, 123 
lethargy and death before the age of 6 months ((Huyghe et al., 2006c) and unpublished observations). 124 
With the exception of testicular degeneration, no peripheral organ failure was observed (Jia et al., 125 
2003, Huyghe et al., 2006a, Huyghe et al., 2006b). Interestingly, mice with selective elimination of 126 
MFP2 from neural cells develop minor neuroinflammation and have an extended lifespan compared to 127 
general knockouts (Verheijden et al., 2013). This suggests that loss of peroxisomal β-oxidation from 128 
non-neural cells (e.g. microglia and/or infiltrating monocytes) worsens the inflammatory state of the 129 
brain. 130 
For unknown reasons, the phenotype of Mfp2
-/-
 mice deviates from the severe neurodevelopmental 131 
pathology of patients with total ablation of MFP2 (Ferdinandusse et al., 2006b). Milder mutations give 132 
rise to degenerative neurological anomalies including ataxia, leukodystrophy and vision/hearing 133 
problems (Ferdinandusse et al., 2006a, Khan et al., 2010, van der Knaap et al., 2012) but it has not 134 
been assessed whether neuroinflammation develops. The precise metabolic role of MFP2 in the 135 
formation and maintenance of the CNS remains unresolved. Apart from increased levels of very long 136 
chain fatty acids, no other metabolic anomalies have been identified (Huyghe et al., 2006a).  137 
 138 
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In this study, we used Mfp2
-/-
 mice as a unique tool to study the cellular and molecular aspects of 139 
neuroinflammation in peroxisomal β-oxidation deficiency.   Specifically, we aimed to molecularly define 140 
the activation state of microglia and to uncover the cellular mechanisms driving the neuroinflammatory 141 
response. Our findings show that Mfp2
-/-
 microglia adopt a strongly proliferative and immunologically 142 
activated phenotype that is neuron-sparing. As this contrasts with microglia in the neurodegenerative 143 
milieu of the SOD1
G93A
 spinal cord (Chiu et al., 2013), we directly compared gene expression and 144 
histological features of microglia in both mouse models.  145 
 146 
MATERIALS AND METHODS 147 
Mouse breeding 148 
The generation of Mfp2
-/-
 mice has been described (Baes et al., 2000). Mfp2
-/- 
mice were bred on a 149 
Swiss/Webster background in the specific pathogen free animal housing facility of the KU Leuven, had 150 
ad libitum access to water and standard rodent food, and were kept on a 12-hour light and dark cycle. 151 
As we did not detect differences between wild type and heterozygous mice in our previous 152 
investigations, they were both used as controls. Unless stated otherwise, all experiments were 153 
performed on 17-20 week old mice with mixed gender and were in accordance with the "Guidelines for 154 
Care and Use of Experimental Animals" and fully approved by the Research Ethical committee of the 155 
KU Leuven (#190/2012).  156 
 157 
Microglia isolation by FACS sorting 158 
Microglia were acutely isolated from Mfp2
-/- 
and control mice (n=4 for each genotype). After 159 
transcardiac perfusion with ice-cold PBS, brains were quickly dissected and mechanically 160 
homogenized with a tissue homogenizer in ice-cold HBSS containing 15mM HEPES and 0.5 % 161 
glucose (De Haas et al., 2007). Cells were filtered over a 70 µm strainer and pelleted at 220 g for 10 162 
min at 4 °C. Contaminating myelin was removed by resuspending the pellet in 25 ml ice-cold 22% 163 
Percoll buffer, overlaying with  5 mL ice-cold PBS followed by centrifugation in a swinging bucket rotor 164 
at 950 g for 25 min at 4 °C (modified from (Olah et al., 2012)). The cells were incubated with mouse 165 
anti-CD45-FITC (eBiosciences 11-0451; 1:40) and mouse anti-CD11b-APC (eBiosciences 17-0112; 166 
1:100) for 30 minutes at 4 °C in the dark. CD11b
high
/CD45
mid 
cells were isolated using an Aria I 167 
fluorescence-activated cell sorter (FACS) (BD Biosciences) equipped with a 488 nm and 633 nm 168 
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laser. Cells with low forward/sideward scatter profile were excluded from the isolation. Microglia yield 169 
ranged between 1 x 10
5
 to 3 x 10
5
 cells/mouse brain. Cells were collected in RNA lysis buffer provided 170 
with the RNeasy microkit (Qiagen, 74004).  Data from FACS sorting of CD11b
high
/CD45
mid
 myeloid 171 
cells were analyzed using BD FACsuite software (BD Biosciences). 172 
 173 
Microarray  174 
Total RNA was isolated from FACS sorted microglia by using the RNeasy Micro kit (Qiagen). The 175 
quality of the RNA samples was determined with an Agilent 2100 Bioanalyzer (Agilent Technologies, 176 
California, USA). Only samples with RIN values (RNA Integrity Number) higher or equal to 8 were 177 
used. The RNA was amplified with the NuGEN amplification kit (Agilent technologies).  For microarray 178 
analysis, the whole genome GeneChip Mouse Gene 1.0 ST Array was used as described previously. 179 
Quality control, amplification, labeling of the samples, hybridization, washing and scanning of the chips 180 
and first-line bioinformatics was carried out at the MicroArray Facility (MAF, VIB, Leuven, Belgium). 181 
The complete dataset is available under GEO record GSE66420. 182 
 183 
Flow cytometry 184 
Brain cells were isolated by Percoll gradient centrifugation as described above. For antibody labeling, 185 
1 x 10
5 
cells were incubated in 200 µl for 20 min at 4 °C with combinations of mouse anti-Cd11b-APC 186 
(1:200) and either rat anti-LY6C-FITC (1:200), rat anti-5E12 (CD39) (1:300) rat anti-FCRLS (1:300) 187 
antibodies (Butovsky et al., 2012, Butovsky et al., 2014). The latter two were detected with goat anti-188 
rat IgG conjugated to FITC (1:300; BioLegend). To demonstrate cell proliferation, bromodeoxyuridine 189 
(BrdU) (Sigma B5002) was dissolved in sterile Dulbecco’s phosphate buffered saline at 37°C and 190 
injected intraperitoneally (50 mg/kg body weight) daily for 3 consecutive days in 12-week-old or 16-191 
week-old Mfp2
 
knockout and wild type littermates. Twelve hours after the last BrdU injection, 192 
proliferating cells were detected using flow cytometry with anti-BrDU antibodies (BrDU Flow Kit; BD 193 
Biosciences). Alternatively, animals were sacrificed for immunohistochemical detection of BrdU.  Flow 194 
cytometry was performed on a FACSVerse (BD Biosciences), and data analyzed with BD FACsuite 195 
software (BD Biosciences). For immunological profiling, CD11b-Pe Cy7 (clone M1/70, Biolegend) was 196 
used in combination with CD11c-APC (clone HL3, BD Pharmingen), F4/80-APC (clone BM8, 197 
eBioscience), CX3CR1-FITC (Goat polyclonal, R&D Systems), CD204-Alexa 647 (clone MR5D3, AbD 198 
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Serotec), CD206-Alexa 647 (clone 2F8, AbD Serotec) or IL10R (Imtec Diagnostics) all at dilutions of 199 
1:200.  200 
 201 
Real time PCR 202 
Real time PCR was performed as previously described (Bottelbergs et al., 2010) using an ABI PRISM 203 
7500 Real Time PCR instrument (Applied Biosystems, Lennik, Belgium). Primers and probes were 204 
either designed using Primer Express Software (Applied Biosystems) (β-actin, iNOS, Tnf sequences 205 
available on request) or ordered from Applied Biosystems as premade Taqman Gene Expression 206 
assays (Il1b, Mm011336189_m1; Il6, Mm01210733_m1; Cx3cr1, Mm0262011_s1; Tgfbr1, 207 
Mm00436964_m1; arginase, Mm00475991_m1; Mrc1, Mm00485148_m1). Assays were performed in 208 
duplicate or triplicate in 10 µL TaqMan Fast Universal PCR Master Mix (Applied Biosystems). Relative 209 
expression levels of the target genes were calculated taking into account the amplification efficiency 210 
as described (Giulietti et al., 2001). The relative expression levels of the target genes were calculated 211 
as a ratio to the housekeeping gene β-actin.  212 
 213 
Bioinformatics 214 
Differential expression of genes between the two conditions is based on the robust multi-array 215 
analysis (RMA) expression values (Irizarry et al., 2003) as obtained with the xps package (version 216 
1.18.1) of BioConductor (www.bioconductor.org). We tested whether it significantly deviates from 0 217 
with a moderated t-statistic (implemented in limma). The resulting p-values are corrected for multiple 218 
testing with Benjamini-Hochberg (Hochberg and Benjamini, 1990) to control the false discovery rate. 219 
In general, differential expression is based on the p-values, corrected for multiple testing (e.g. all 220 
probes with a corrected p-value less than 0.01) together with a cut-off on the fold-change of 1.5. 221 
Pathway analysis is based on information provided by The Ingenuity Knowledge Base. For data 222 
interpretation and visualization Ingenuity pathway analysis (IPA) and the functional annotation tool 223 
KEGG (Kyoto Encyclopedia for Genes and Genomes database) from DAVID (Database for 224 
Annotation, Visualization and Integrated Discovery v6.7) was used. In addition, the dataset from Mfp2
-
225 
/-
 microglia was compared to transcriptomics datasets based on either RNA-sequencing of microglia in 226 
homeostatic conditions and from SOD1
G93A
 mice (Chiu et al., 2013) (GEO dataset GSE43366) or gene 227 
expression profiling of microglia in homeostatic conditions using a NanoString nCounter platform 228 
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(Butovsky et al., 2014). The RPKM gene levels from the RNA-seq experiment were converted to fold 229 
change as compared to control values. Differentially expressed genes (fold > 1.5, p-value < 0.01) were 230 
used for all analyses.  231 
 232 
Histology 233 
Anesthesia of the mice and tissue processing and immunohistochemical (IHC) staining were 234 
performed as described (Hulshagen et al., 2008). Routinely, paraffin sections (7 µm) were used for 235 
immunofluorescent stainings. The following primary antibodies were used: polyclonal rabbit anti-Iba1 236 
(1:500; Wako D19-19741), rabbit anti-phospho-S6 ribosomal protein mAb (Ser235/236) (1:400; Cell 237 
signaling D57.2.2E), rabbit Cathepsin D (1:200 Santa Cruz), Lamp2/Mac3 (1:100, BD Pharmingen), 238 
rat Anti-BrDU mAb (1:100; AbD Serotec OBT0030), rabbit 3-nitrotyrosine (1:100; Millipore 06-284), 239 
and rabbit 4-hydroxynonenal (1:500; Millipore 393204). Cryo sections were used for staining with 240 
polyclonal rabbit anti-P2RY12 (1:500; provided by Prof. O. Butovsky, Boston, USA). Frozen sections 241 
of spinal cord of endstage SOD1
G93A
 mice were kindly provided by Prof. L. Van Den Bosch (VIB and 242 
KU Leuven, Belgium). After incubation with primary antibodies overnight at room temperature (at 4°C 243 
for anti-P2RY12 staining) HRP-labeled secondary antibodies (1:200) were applied for 1 hour, followed 244 
by fluorescent labeling with a cyanine 2 (FITC) TSA kit (Perkin Elmer Life sciences, Boston, USA). 245 
P2ry12 antibodies were detected with goat anti-rabbit IgG conjugated to Alexa647 (1:300; Life 246 
technologies A21244). When double immunolabeling was performed, sets of primary and secondary 247 
antibodies were applied sequentially. As second fluorescent labels, cyanine 3 TSA kits (Perkin-Elmer) 248 
were used. Images were acquired with a motorized inverted IX-81 microscope connected to a CCD-249 
FV2T digital camera (Olympus, Aartselaar, Belgium) and processed with LSM Image browser software 250 
(Zeiss, Germany). Microglia cell numbers were quantified on Iba-1 immunofluorescent stained paraffin 251 
sections (7 µm) around the sagittal midline (n=4). Within one plane (20 x magnification), only Iba-1-252 
positive cells that fully colocalized with DAPI-positive nuclei were counted in the different regions of 253 
the brain, namely cornu ammonis (CA) 1-3 and dentate gyrus (DG) of hippocampus, somatosensory 254 
cortex, motor cortex and dorsal pons. Microglia number/frame was corrected for surface area. 255 
Quantification of neuronal numbers in CA3 of hippocampus was performed on cresyl violet stained 256 
sections (n=5) in a similar way as described for microglia. Only cells in which the Nissl substance was 257 
clearly visible were quantified.   . 258 
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 259 
In vivo LPS challenge and cytokine measurements 260 
  261 
Mfp2
-/- 
and control mice 14 weeks of age received an intraperitoneal injection of LPS (1mg/kg, Sigma, 262 
L4391) or sterile saline vehicle in a total volume of 100µl. Four hours later, mice were sacrificed, 263 
plasma and brain regions were collected and flash frozen in liquid nitrogen. Brainstem was 264 
homogenized 1:10 (w/v) in ice-cold PBS containing a cocktail of protease inhibitors (Roche) and 265 
lysates were cleared by centrifugation at 14000g for 20 min at 4°C.  Immunoreactive levels of TNF, 266 
IL1β and IL6 were measured in plasma and brainstem lysates by using a cytometric bead array mouse 267 
soluble protein flex set system (BD Biosciences). The samples were prepared according to the 268 
manufacturer’s instructions and analyzed on a FACSCanto HTS (BD Biosciences) and analyzed by 269 
FCAP array software (BD Biosciences). 270 
 271 
Statistical analysis 272 
One-way ANOVA was carried out using Graphpad Prism 3.0 software (San Diego, CA). For 273 
microarray data, p-values are corrected for multiple testing with Benjamini-Hochberg (Hochberg and 274 
Benjamini, 1990).  275 
276 
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RESULTS 277 
No invasion of Ly6C
+
 monocytes but proliferation of resident microglia in Mfp2
-/- 
brain 278 
One of the most striking neuropathological hallmarks of Mfp2
-/-
 mice is the development of extensive 279 
neuroinflammation involving astro- and microgliosis (Huyghe et al., 2006c, Verheijden et al., 2013). 280 
During the disease course, Iba1
+ 
brain macrophages acquire an activated phenotype and display 281 
enlarged cell bodies and a deramified morphology together with increased F4/80 expression 282 
(Verheijden et al., 2013). In order to estimate whether these cells increase in number, Iba1
+
 cells were 283 
quantified in different regions of the CNS of mice at end stage (5 months old). In hippocampus, motor 284 
cortex and pons, microglia/macrophage numbers were 4-6 fold increased in Mfp2
-/-
 compared to 285 
control brain (Fig. 1A). To investigate whether this increase arises from influx of peripheral monocytes 286 
or accumulation of resident microglia, we evaluated the presence of markers that are respectively 287 
expressed by blood monocytes (Ly6C) and resident microglia (CD39, FCRLS). Indeed, Butovsky et al 288 
recently showed that the expression of Ly6C and CD39/FCRLS effectively distinguishes non-289 
overlapping populations of peripheral inflammatory monocytes and CNS-resident microglia in mice 290 
(Butovsky et al, 2012; Butovsky et al, 2014). The efficacy of these discriminating markers has been 291 
convincingly proven in a mouse model of ALS (SOD1
G93A
)(Butovsky et al., 2012, Butovsky et al., 292 
2014). FACS analysis on brain homogenates of endstage Mfp2
-/-
 mice showed that almost all CD11b
+
 293 
cells are negative for the monocyte marker Ly6C (> 99%) (Fig.1B). In contrast, the vast majority of 294 
CD11b
+
 cells (> 97%) is positive for CD39 and FCRLS, two specific markers for resident microglia 295 
(Fig. 1C-D). Moreover, all CD11b
+ 
cells are CD45
dim
, which is another characteristic of resident 296 
microglia (data not shown). Together, these data show that the expanded myeloid population is of 297 
local origin allowing to further designate these cells as microglia.  298 
Having excluded influx of inflammatory monocytes in the Mfp2
-/-
 brain, we next wanted to verify 299 
whether the accumulation of brain myeloid cells originates from proliferation of CNS resident microglia. 300 
We analyzed BrdU incorporation in microglial cells and indeed found significantly increased numbers 301 
of proliferating Iba1
+
/BrdU
+
 cells by IHC analysis (Fig. 1E) and Cd11b
+
/BrdU
+
 cells by FACS analysis 302 
in Mfp2
-/- 
compared to control mice (Fig. 1F,G). Together, these data demonstrate that the 303 
inflammatory response in Mfp2
-/-
 brain is governed by proliferation of resident microglia and not by 304 
infiltration of peripheral cells. 305 
 306 
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Defining the molecular signature of a non-neurodegenerative microglia phenotype 307 
As microgliosis in Mfp2
-/-
 mice is confined to gray matter areas such as cortex, hippocampus and 308 
brainstem (Verheijden et al., 2013), we performed double immunofluorescence stainings with 309 
microglial and neuronal markers.  We observed that microglia enwrap neuronal cell bodies (Fig. 2A-F), 310 
suggesting that microglia in Mfp2
-/- 
mice become activated in response to neuronal demise, analogous 311 
to several disease models of neurodegenerative disorders. However, previous FluoJade and 312 
caspase/TUNEL stainings did not show evidence for neuronal damage nor death in the CNS of Mfp2
-/-
 313 
mice (Huyghe et al., 2006c). To further confirm the conservation of neurons, we counted neuron 314 
numbers in the CA3 region of the hippocampus of endstage Mfp2
-/-
 mice (Fig. 2G-I). We did not find 315 
significant differences between Mfp2
-/-
 and control mice. Also in other brain regions, we could not 316 
detect an overt reduction of neuron numbers (not shown). The microglia microenvironment in Mfp2
-/-
 317 
brain thus deviates from the milieu in neurodegenerative disorders. We therefore characterized the 318 
molecular signature of this non-neurodegenerative microglia phenotype and performed microarray 319 
analysis on acutely isolated microglia (CD11b
+
/CD45
dim
) from whole brain of 5 months old control and 320 
Mfp2
-/- 
mice (Fig. 3A,B). We found that 983 genes were differentially expressed in Mfp2
-/- 
compared to 321 
control microglia (288 downregulated, 695 upregulated; fold ≥ 1.5, p-value < 0.01) (Fig. 3C). The top 322 
50 up- and downregulated genes, the unsupervised hierarchical clustering of RMA values and the 323 
principle component analysis of gene expression data are shown in Suppl. Fig.1.  Pathway enrichment 324 
by Ingenuity and DAVID analysis demonstrated pronounced induction of pathways related to protein 325 
translation, cellular growth and proliferation, such as Eif2 signaling, mTOR signaling and regulation of 326 
eIF4 and p70S6K signaling  (Fig. 3D and Suppl. Table 1). Activation of mTOR was validated by IHC, 327 
showing increased phosphorylation of the downstream target ribosomal S6 protein (pS6) in Mfp2
-/-
 328 
compared to wild type microglia (Fig. 3E,F). The transcription factor Hypoxia-inducible factor 1-alpha 329 
(HIF1α), another downstream target of mTOR (Duvel et al., 2010), was significantly induced according 330 
to the microarray data, which was further supported by elevated transcripts of several enzymes of the 331 
glycolytic pathway and VEGF (Suppl. Table 1). Interestingly, the regulatory subunit of 5' AMP-332 
activated protein kinase (AMPK) that inhibits mTOR in conditions of cellular energy depletion, was 333 
downregulated by 50%. The enrichment of mTOR and eIF2 signaling is in accordance with the strong 334 
proliferative response and cellular growth observed in Mfp2
-/- 
microglia.  335 
 336 
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Microglia in Mfp2
-/-
 brain are not phagocytic and do not produce reactive oxygen/nitrogen 337 
species 338 
We compared the transcriptional signature of Mfp2
-/-
 microglia residing in a neuron-sparing milieu, with 339 
the previously published neurodegeneration-specific microglial signature in SOD1
G93A
 mice, a model 340 
for ALS (GEO dataset GSE43366)(Chiu et al., 2013). The most pronounced difference between the 341 
Mfp2
-/-
 and SOD1
G93A
 model was the strong enrichment of the KEGG pathway Lysosome in SOD1
G93A 
342 
microglia (37.9% of genes related to Lysosome upregulated) (Fig. 4B) whereas this was less obvious 343 
for Mfp2
-/- 
microglia (11.7% of genes upregulated) (Fig. 4A). Comparison for enriched functions 344 
between the two models using Ingenuity analysis demonstrated marked enrichment for ‘phagocytosis’,  345 
'cytoskeletal organization’ and ‘respiratory burst’ in the SOD1
G93A
 as compared to Mfp2
-/-
 microglia 346 
(Fig. 4C). As these data suggest that microglia in Mfp2
-/-
 mice do not acquire phagocytic properties, in 347 
contrast to microglia in a neurodegenerative disease model (SOD1
G93A
), we performed IHC for 348 
markers associated with lysosomal activation and phagocytosis. There was no increased 349 
immunoreactivity of Cathepsin D (Fig. 4D,E), LAMP2/MAC3 (Fig. 4G,H) and CD68 (not shown) in 350 
brain of Mfp2
-/-
 versus control mice (shown for visual cortex and brainstem). In contrast, we detected 351 
clear positive staining for these markers in the lumbal spinal cord of endstage SOD1
G93A
 mice (Fig. 352 
4F,I).   353 
The low expression of ‘respiratory burst’ genes in Mfp2
-/-
 as compared to SOD1
G93A
 microglia 354 
comprised normal levels of Nos2, Nox1 and Nox2 (Cybb) versus controls. In contrast, SOD1
G93A
 355 
microglia showed a very strong upregulation of Cybb compared to control microglia (> 40 fold) (Chiu et 356 
al., 2013). As reactive oxygen and nitrogen species are known to be important mediators of 357 
neurotoxicity, and upregulation might take place at the posttranscriptional level, we further evaluated 358 
oxidative stress markers. IHC stainings for nitrated proteins (Fig. 4J-L) and lipid peroxidation (4HNE, 359 
not shown) were not detectable in Mfp2
-/-
 brain (Fig. 4K), whereas both were positive in SOD1
G93A
 360 
spinal cord (Fig. 4L and data not shown). 361 
In summary, despite their chronic active state, Mfp2
-/-
 microglia do not upregulate pathways 362 
associated with phagocytic clearance, lysosomal activity and reactive oxygen/nitrogen species 363 
production. This is in striking contrast to the neurodegeneration-specific microglial signature of 364 
SOD1
G93A 
mice. 365 
 366 
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Mfp2
-/-
 microglia are immunologically activated but not polarized  367 
In response to disruption of CNS homeostasis by infectious or sterile conditions, reactive microglia can 368 
produce pro-inflammatory cytokines such as TNF. Chronic release of these substances by microglia 369 
can affect neuronal viability (Block et al., 2007). In contrast, the induction of an anti-inflammatory 370 
microglia phenotype is generally linked to neuroprotection (Kigerl et al., 2009, Liao et al., 2012). In 371 
view of preserved neuron numbers in Mfp2
-/-
 mice and the absence of a neurodegeneration-specific 372 
microglial signature, we explored transcript levels of genes associated with pro- and anti-inflammatory 373 
activation in the micro-array dataset. Microglia in Mfp2
-/- 
mice are clearly immunologically activated as 374 
several genes encoding cytokines (Il1b, Tnf, Il12b), chemokines (Ccl5, Ccl2) and surface markers 375 
(Itgax, Emr1, Cd83, Cd86) associated with inflammatory activation were strongly induced (Fig. 5A,C). 376 
Remarkably, the expression of several key pro-inflammatory genes was unchanged (Nos2, Il12a, 377 
Cxcl9, Ifnb1, Icam1) or even downregulated (Il6), suggesting that microglia in Mfp2
-/-
 mice do not 378 
acquire a typical pro-inflammatory activation state. However, Mfp2
-/-
 microglia could also not be 379 
categorized as anti-inflammatory, because typical anti-inflammatory genes were either induced (Arg1, 380 
Msr1) or repressed (Mrc1, Stab1) (Fig. 5A-C). qRT-PCR and FACS analysis of some key inflammatory 381 
markers further confirmed that the microglia activation state in Mfp2
-/-
 mice cannot be categorized as  382 
pro- or anti-inflammatory (Fig. 5B,D). Analysis of cytokine levels in brain homogenates revealed that 383 
despite strongly increased transcript levels of Tnf and Il1b in microglia, the respective cytokine levels 384 
were not detectable (TNF) or only 1.5 fold increased (IL1β) (not shown) in Mfp2
-/- 
brain, further 385 
supporting the absence of a typical pro-inflammatory effector state. Interestingly, after intraperitoneal 386 
injection of LPS, both transcript (Tnf, Il1b) and protein levels (IL1β, IL6 and TNFα) were more strongly 387 
induced in Mfp2
-/- 
compared to control mice, consistent with a primed state (Perry and Holmes, 2014) 388 
(Fig. 5E,F). In order to exclude that this particular immunological state of microglia is induced by 389 
systemic inflammation, we analyzed cytokine levels in plasma (Il1β, Il6, TNFα) and the leucocyte 390 
profile in blood. There were however no signs of peripheral inflammatory anomalies in Mfp2
-/-
 mice 391 
and after LPS administration cytokine levels increased similarly in control and mutant mice (data not 392 
shown).  393 
It thus seems that Mfp2
-/-
 microglia exhibit an immunologically activated and primed state, but they are 394 
not polarized and only acquire a typical pro-inflammatory effector state after a secondary stimulus.  395 
 396 
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 397 
 398 
The homeostatic microglial signature is downregulated in Mfp2
-/- 
microglia 399 
Several research groups recently reported the specific transcript signature of homeostatic microglia 400 
(Gautier et al., 2012, Chiu et al., 2013, Hickman et al., 2013, Butovsky et al., 2014) by comparing the 401 
transcriptomes of microglia with those of other CNS cell types and/or peripheral myeloid cells. This 402 
resulted in the identification of specific markers of microglia in their surveillance mode. When 403 
comparing our data set with the homeostatic microglial signature, it was conspicuous that the bulk of 404 
microglia specific genes was significantly suppressed in Mfp2
-/- 
microglia (46% when compared with 405 
Butovsky et al.(Butovsky et al., 2014) (Fig. 6A) and 53 % compared with Chiu et al. (Chiu et al., 406 
2013)), whereas only a few were upregulated (6-9%). These data demonstrate that in the inflamed 407 
Mfp2
-/- 
brain, microglia loose typical features related to their homeostatic function. In order to validate 408 
the microarray data, we performed qRT-PCR of Cx3cr1 and Tgfbr1 on isolated microglia (Fig. 6B,C) 409 
and IHC analysis of P2RY12 (Fig. 6D,E) which confirmed the downregulation of these surface markers 410 
in Mfp2
-/- 
microglia. FACS analysis for CX3CR1 and IL10R showed a clear reduction in CX3CR1 411 
expression and a slight reduction in IL10R expression (Fig. 6F,G). Taken together, a hallmark of the 412 
microglia phenotype in Mfp2
-/- 
brain is the loss of surface and other markers that were shown to be 413 
highly and exclusively expressed in these cells in homeostatic conditions.  414 
 415 
 416 
 417 
 418 
  419 
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DISCUSSION 420 
This study contributes to a better understanding of the wide spectrum of phenotypes that microglia can 421 
adopt in the diseased brain. We determined the microglial signature in a murine model of peroxisomal 422 
β-oxidation deficiency in which robust and chronic inflammation in the gray matter occurs in the  423 
absence of neuronal loss. We show that the resident microglia in Mfp2
-/-
 mice proliferate, are 424 
permanently in an activated non-phagocytic state and lose their typical homeostatic markers. Our data 425 
prove that microglia can remain in a reactive state without acquiring overt neurotoxic and phagocytic 426 
properties. 427 
 428 
As infiltrating bone marrow-derived monocytes may have a major impact on the pathological course of 429 
neurological conditions (Prinz and Mildner, 2011, Yamasaki et al., 2014), it was of prime importance to 430 
establish the source of the expanded microglial compartment in Mfp2
-/-
 mice. Analysis of specific 431 
markers corresponding to peripheral monocytes and resident microglia clearly showed that the 432 
myeloid cells in Mfp2
-/-
 brain, even at late stages of disease, solely derive from local microglia. This 433 
differs from the neuroinflammatory demyelination condition in the peroxisomal β-oxidation disorder, 434 
ccALD in which the fast progressive phase coincides with opening of the blood brain barrier (Kemp et 435 
al., 2012).  436 
 437 
Although the immunological profile of Mfp2
-/- 
microglia is clearly distinct from naive microglia, the 438 
affected cytokines and inflammatory mediators could not be clustered in currently known pro- or anti-439 
inflammatory states. In contrast to acute insults to the brain, where microglia switch from an initial pro-440 
inflammatory to a resolving anti-inflammatory state, the microglial phenotype in chronic sterile stress 441 
conditions can be very heterogeneous.  In the SOD1
G93A
 mouse model of ALS, microglia were shown 442 
to convert during the course of disease from an alternatively activated to a classically activated state 443 
(Liao et al., 2012). The latter were shown to be neurotoxic to motor neurons in vitro. It is now 444 
recognized that microglia induce inflammatory markers in the aged rodent brain and it is hypothesized 445 
that this modest chronic neuroinflammation impairs neuronal functioning (Norden and Godbout, 2013). 446 
Age is not contributing to the inflammatory response in our model as mice only survive up to 5-6 447 
months of age. It remains however unsolved whether long-term activation of microglia is necessarily 448 
deleterious for neural cells (Biber et al., 2014). Interestingly, crucial players in the neurotoxic 449 
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properties are reactive oxygen and nitrogen species (Block et al., 2007, Brown and Neher, 2014). 450 
Although a set of pro-inflammatory surface and cytokine markers are induced in Mfp2
-/- 
microglia, the 451 
genes responsible for generation of reactive oxygen and nitrogen species are not upregulated, even at 452 
endstage of disease. The induction of Arg1, a well characterized anti-inflammatory marker gene, also 453 
indicates that Mfp2
-/-
 microglia are rather protective for their environment than toxic. Indeed, the 454 
enzyme arginase 1 utilizes, similar to iNOS, arginine as a substrate, but converts it to products that 455 
serve as precursors in repair processes and not to destructive nitrogen species (Lange et al., 2004, 456 
Estevez et al., 2006). 457 
 458 
Gene expression screening and histological analyses further indicated absence of lysosomal activity 459 
and cytoskeletal remodeling that normally accompany phagocytosis. This is in sharp contrast with the 460 
gene expression signature of SOD1
G93A
 microglia in which these pathways were strongly induced 461 
(Chiu et al., 2013). In the latter model, microglia respond to early changes in motor neurons and 462 
develop phagocytic and neurotoxic properties even in a presymptomatic stage (Sanagi et al., 2010). 463 
On the contrary, reactive microglia in Mfp2
-/-
 brain seem to get stuck in their graded response from a 464 
ramified to a fully activated phagocytic state. This raises the question whether Mfp2
-/-
 microglia have 465 
the ability to develop lysosomal activity and execute phagocytosis. In this respect it is important to 466 
note that cathepsin D positive microglia were present in cerebellar white matter (data not shown), 467 
where we previously showed degeneration of Purkinje cell axons (Verheijden et al., 2013), indicative 468 
of a proper phagocytic function. Microglia in MFP2 deficient mice thus transform for a prolonged 469 
period in a reactive state that lacks neurodestructive behavior within their lifetime. It needs to be 470 
elucidated whether this state is triggered by cell autonomous processes in microglia resulting from 471 
peroxisomal β-oxidation inactivity or by microglial responses to MFP2 deficiency in neighbouring cells 472 
or a combination of these mechanisms.  The fact that the microglial reactivity is confined to the gray 473 
matter strongly suggests that metabolic distress caused by peroxisomal MFP2 deficiency in neurons 474 
contributes to pathology.  475 
In view of the seemingly harmless microglial activation, the question arises whether this contributes to 476 
disease pathogenesis in Mfp2
-/-
 mice as increasing microgliosis coincides with the neurological 477 
symptoms. In this respect, it should be emphasized that the most prominent coordinated change in 478 
Mfp2
-/-
 microglia is rather a loss-of-function than a toxic-gain-of-function. Several research groups 479 
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recently defined the unique transcriptome signature of homeostatic microglia by comparison with their 480 
neural cell neighbors and myeloid cell family members (Gautier et al., 2012, Chiu et al., 2013, 481 
Hickman et al., 2013, Butovsky et al., 2014). These typical microglial markers were generally 482 
downregulated in Mfp2
-/-
 microglia pointing to a loss of their surveillance state.  Butovsky et al recently 483 
reported that the microglia specific gene signature is mainly driven by transforming growth factor β 484 
(TGFβ) and that loss of TGFβ signaling leads to downregulation of the homeostatic gene signature 485 
(Butovsky et al., 2014). In Mfp2
-/-
 microglia the expression of Tgbr1 was downregulated, probably 486 
contributing to their loss-of-homeostatic-function phenotype. A large fraction of the downregulated 487 
genes encode cell surface proteins such as the purinergic receptors P2RY12 and P2RY13. It should 488 
however be noted that this loss of microglial membrane proteins is selective as several others are 489 
either unchanged (e.g. P2RY6) or increased (e.g. P2RX4) in expression. It is plausible that these 490 
alterations will perturb the microglial communication with the microenvironment or that chronic 491 
deprivation of homeostatic microglial properties impairs neurological function. It was indeed shown 492 
that lack of CX3CR1 signaling in microglia perturbs synaptic function in the postnatal period resulting 493 
in persistently disturbed brain connectivity and behavioral disorders (Zhan et al., 2014). Furthermore, 494 
loss of microglia in adulthood was proven to impact on memory and motor learning through impaired 495 
synapse formation, emphasizing the importance of proper neuron-microglia crosstalk in normal brain 496 
functioning (Parkhurst et al., 2013).  497 
 498 
Whereas the primary trigger for microglia activation in Mfp2
-/- 
brain remains unknown, we found that 499 
mTOR and other pathways driving protein synthesis were induced in the reactive microglia. Activation 500 
of these pathways leads to cell proliferation and growth, in line with the observed morphological and 501 
mitogenic response of Mfp2
-/-
 microglia. The pathways downstream of mTOR are known to be 502 
involved in ribosomal activity, protein synthesis and energy generation through induction of HIF1α, 503 
glycolysis, and enhanced mitochondrial functioning (Hay and Sonenberg, 2004, Duvel et al., 2010). In 504 
fact, little is known on the role of mTOR in the diverse microglial phenotypes.  In vitro experiments with 505 
primary microglia and BV2 cells showed increased mTOR signaling after exposure to hypoxia, LPS or 506 
a mixture of cytokines (Lu et al., 2006). Mouse models with various neurological conditions such as 507 
spinal cord injury and epilepsy, were shown to improve when treated with mTOR inhibitors but the 508 
impact on the inflammatory reaction remains poorly documented (Sekiguchi et al., 2012, van Vliet et 509 
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al., 2012, Lu et al., 2014). Interestingly, mTOR was recently identified as a novel factor involved in 510 
macrophage polarization although contradictory findings were reported whether mTOR activation 511 
biases the cytokine response towards a pro- or an anti-inflammatory state (Byles et al., 2013, Luo et 512 
al., 2014). In addition, it was recently shown that the AKT-mTOR-HIF1α pathway is instrumental for 513 
‘training’ of macrophages whereby cytokine expression is enhanced following a prior exposure to β-514 
glycan (Cheng et al., 2014, Saeed et al., 2014). This signaling orchestrates a switch in macrophages 515 
from oxidative metabolism to aerobic glycolysis. In this respect, the upregulation of the mTOR 516 
pathway in Mfp2
-/-
 microglia, may play a broader role than only sustain growth and proliferation. The 517 
activation of the transcription factor HIF1α and its downstream glycolytic enzymes might play a pivotal 518 
role in the primed state of Mfp2
-/-
 brain and possibly in other chronic neuroinflammatory states. In view 519 
of the premise that primed microglia in neurodegenerative diseases become detrimental after a 520 
systemic insult such as infection or illness, it is important to further investigate whether targeting 521 
mTOR can modify the microglia expression pattern in Mfp2
-/-
 mice and in other neuroinflammatory 522 
conditions.  523 
 524 
 525 
In conclusion, our data indicate that chronically reactive microglia in Mfp2
-/-
 brain adopt an 526 
immunologically activated but non-polarized phenotype that is marked by morphological and metabolic 527 
adaptations. These microglia act in a pro-survival environment without overt neuronal demise, 528 
although an adverse effect on neuronal functioning through loss of microglial homeostatic functions 529 
cannot be excluded.  530 
 531 
  532 
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FIGURE LEGENDS 710 
Figure 1. Increased numbers of myeloid cells in Mfp2
-/- 
brain do not derive from influx of 711 
peripheral  monocytes but from proliferation of resident microglia 712 
(A) Immunofluorescent staining for the microglia/macrophage marker Iba-1 reveals an increased 713 
number and altered shape of brain myeloid cells in the CA3 region of hippocampus in Mfp2
-/-
 mice at 5 714 
months compared to an age-matched control. Quantification of Iba-1
+
 cells in different brain regions 715 
shows increased microglia cell numbers in hippocampus (hpc), motor cortex (mcor) and pons of Mfp2
-
716 
/- 
mice (** p < 0.01). Nuclei are stained blue with DAPI. (B) FACS analysis of Ly6C expression in 717 
CD11b-gated cells (n = 6 per group). Quantification shows that nearly all CD11b
+
 cells in brain of 718 
control and Mfp2
-/- 
mice are Ly6c negative. (C) Nearly all Cd11b
+
 myeloid cells from control and Mfp2
-/- 
719 
brain express the microglial specific surface marker CD39 (n = 6 per group). (D) Nearly all Cd11b
+
 720 
myeloid cells from control and Mfp2
-/- 
brain express the microglial specific surface marker FCRLS (n = 721 
4 per group). All FACS data are presented as mean ± SEM (n = 4- 6 per group) **p < 0.01.  (E) BrdU 722 
incorporation (green) in Iba-1
+ 
cells (red) in Mfp2
-/-
 but not in control brain using immunofluorescent 723 
staining. Nuclei are stained blue with DAPI. (F,G) BrDU incorporation in CD11b-gated cells is higher in 724 
Mfp2
-/-
 compared to control mice (n = 3-4 per group, mean ± SEM)  *p < 0.05.  725 
 726 
Figure 2. Abundant microglia-neuron contacts but no neuronal loss in Mfp2
-/- 
mice 727 
(A-D) Activated microglia (Iba1
+
, green) enwrap cell bodies (DAPI, blue) in the CA3 region of the 728 
hippocampus in Mfp2
-/-
 mice (C,D)  but not in control (A,B). B and D are magnifications of the 729 
highlighted area in A and C, respectively. Nuclei are stained blue with DAPI. (E) F4/80
+
 cells contact 730 
NeuN
+
 neurons in the brainstem of Mfp2
-/-
 mice. (F) Magnification of E. (G – I) H&E staining and 731 
quantification in the CA3 region of hippocampus reveals preservation of neurons in Mfp2
-/-
 mice.  732 
 733 
Figure 3. Transcriptomics analysis on acutely isolated microglia from control and Mfp2
-/- 
mouse 734 
brain  735 
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(A,B) Cd11b/Cd45 FACS sorting of microglia isolated from control (A) and Mfp2
-/- 
(B) mouse brain. (C) 736 
Volcano plot of differentially expressed  genes of Mfp2
-/- 
 versus control microglia (cut-off: 0.75 ≥ fold 737 
change ≥ 1.5; p < 0.01). (D) The 10 most upregulated  pathways after applying the canonical pathway 738 
enrichment tool of Ingenuity software on the microarray dataset of Mfp2
-/-
 microglia (differentially 739 
expressed genes: 0.75 ≤ fold ≤1.5; p-value 0.01 ). (E,F) Increased IHC staining for phosphorylated 740 
ribosomal S6 (pS6, green), a downstream target of mTOR, in Iba1
+
 microglia (red) in Mfp2
-/- 
mice (F) 741 
as compared to control (E), shown for thalamus region. 742 
 743 
Figure 4. Differences in expression of lysosomal, phagocytic and nitrosative stress markers in 744 
Mfp2
-/- 
versus SOD1
G93A 
microglia 745 
(A-B) After transcriptomics analyses of Mfp2
-/- 
microglia (A) and SOD1
G93A
 microglia 
 
(B) (data from 746 
GEO GSE43366) the expression of genes associated with the Lysosome (mmu04142) KEGG 747 
pathway were plotted. The percentage of genes of this pathway differentially expressed in both mouse 748 
models is shown. (C) Heatmap for enriched functions of SOD1
G93A
 microglia as compared to Mfp2
-/- 
749 
microglia (Ingenuity analysis). Enrichment is depicted as activated (orange), not enriched (white) or 750 
deactivated (blue). Red arrows point to functions related to phagocytosis, green arrows to growth and 751 
proliferation.  (D-F) Staining of the lysosomal marker Cathepsin D (green) in visual cortex of control 752 
(D) and Mfp2
-/-  
 mice (E) and in spinal cord of endstage SOD1
G93A
 mice (F). (G-I) Co-staining of the 753 
microglial marker Iba1 (red) and the lysosomal marker LAMP2/MAC3 (green) in brainstem of control 754 
(G) and Mfp2
-/-  
mice (H) and in spinal cord of endstage SOD1
G93A
 mice (I). White arrowheads point to 755 
LAMP2
+
 microglia. (J-L) Staining for nitrosylated proteins (green) in visual cortex of control (J) and 756 
Mfp2
-/-  
mice (K) and in spinal cord of endstage SOD1
G93A
 mice (L). Nuclei are stained blue with DAPI. 757 
 758 
Figure 5. The immunological profile of Mfp2
-/- 
microglia is not polarized to a pro- or anti-759 
inflammatory state  760 
 (A) Relative transcript levels of pro-inflammatory (dark gray bars) and anti-inflammatory (white bars) 761 
activation markers as determined by microarray analysis in Mfp2
-/-
 microglia compared to wild type 762 
(n=4). (B) qRT-PCR analyses of the pro-inflammatory markers IL1β and IL6 and the anti-inflammatory 763 
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marker Arg-1 confirm micro-array data and indicate that microglia are not unequivocally polarized. 764 
mRNA expression levels were normalized to β-actin. Data are presented as mean ± SEM (n = 3-4). * p 765 
< 0.05; ** p < 0.01. (C) Surface markers expression associated with classical (gray) and alternative 766 
(white) macrophage activation as determined by microarray analysis. (D) FACS analysis of CD11b
+
 767 
microglia shows increased expression of CD11c and F4/80 surface markers associated with classical 768 
activation. There is also increased expression of the anti-inflammatory marker CD204
pos
 (Msr1) as 769 
well as an increase in the proportion of microglia that are CD206
neg
 (Mrc1) (representative experiment 770 
out of two). (E-F) Mfp2
-/-
 and control mice (n=3-5) were challenged with intraperitoneal LPS and 771 
brainstem tissue was analyzed after 4 hrs. Transcripts (E) and cytokine levels (F) of Il1b, Il6 and Tnf 772 
were more elevated in Mfp2
-/-
 as compared to control mice. # = not detectable, * p<0.05, ** p < 0.01, 773 
***p<0.001. 774 
 775 
Figure 6. Repression of homeostatic gene signature in Mfp2
-/- 
microglia 776 
(A) Heatmap showing expression values of signature genes of microglia (according to Butovsky et al, 777 
2013) in control versus Mfp2
-/-
 microglia. In Mfp2
-/-
 microglia, 40 out of 86 genes are significantly 778 
downregulated (47%). Expression values are expressed as robust multi-array analysis (RMA). (B,C) 779 
qRT-PCR confirms the downregulation of the microglia-enriched genes Cx3cr1 (A) and Tgfbr1 (B) in 780 
Mfp2
-/-
 microglia. Expression levels were normalized to β-actin. Data are presented as mean ± SEM (n 781 
= 3-4, ** p < 0.01; *** p < 0.001). (D,E) Immunohistochemical staining confirms downregulation of the 782 
purinergic receptor P2RY12 on microglia of Mfp2
-/- 
as compared to wild type mice. (F,G) FACS  783 
analysis of CD11b
+
 microglia shows reduced expression of CX3CR1 and to a lesser extent of IL10R  784 
in Mfp2
-/-
 microglia (1 experiment out of 2 with similar data). 785 
 786 
Supplemental figure 1 Transcriptomics analysis of isolated microglia from Mfp2
-/- 
and control 787 
brain 788 
(A) Heatmap and unsupervised hierarchical clustering of RMA values. (B) Principle component 789 
analysis (PCA) of gene expression data. (C) Heatmaps of top 50 genes upregulated and 790 
downregulated in Mfp2
-/- 
as compared to wild type microglia, ranked by fold change. 791 
 792 
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Supplemental Table 1: Altered gene expression in Mfp2-/- microglia according to micro-array 
analysis 
Symbol Name Fold 
change 
INFLAMMATION    
Chemokines and Cytokines   
Ccl2 chemokine (C-C motif) ligand 2 2.04 
Ccl3 chemokine (C-C motif) ligand 3 2.55* 
Ccl4 chemokine (C-C motif) ligand 4 2.91* 
Ccl5 chemokine (C-C motif) ligand 5 1.87* 
Ccl12 chemokine (C-C motif) ligand 12 2.76** 
Ccl24 chemokine (C-C motif) ligand 24 0.51*** 
Cxcl10 chemokine (C-X-C motif) ligand 10 2.16* 
Cxcl13 chemokine (C-X-C motif) ligand 13 12.97* 
Cxcl16 chemokine (C-X-C motif) ligand 16 2.50*** 
Spp1 secreted phosphoprotein 1 8.25** 
Il1b interleukin 1 beta 3.23** 
Il12b interleukin 12b 2.33** 
Tnf tumor necrosis factor 2.32* 
Il6 interleukin 6 0.70* 
Toll-like receptors   
Tlr2 toll-like receptor 2 1.74** 
Tlr3 toll-like receptor 3 0.65** 
Tlr4 toll-like receptor 4 0.70** 
Antigen presenting cell markers   
Itgax integrin alpha X 5.28*** 
Nrp1 neuropilin 1 3.77*** 
Cd83 CD83 antigen 3.55*** 
Cd86 CD86 antigen 1.37* 
Cd80 CD80 antigen 0.94 
Neurotoxicity     
Nos2 nitric oxide synthase 2, inducible 0.94 
Cybb cytochrome b-245, beta polypeptide 1.61 
Cyba cytochrome b-245, alpha polypeptide 1.45* 
Ncf4 neutrophil cytosolic factor 4 1.12 
Ncf1 neutrophil cytosolic factor 1 0.94 
CELL SURVIVAL   
Cell death     
Abl1 C-abl oncogene 1, non-receptor tyrosine kinase 0.63* 
Anxa5 Annexin A5 2.86** 
Atf5 Activating transcription factor 5 1.79** 
Bag1 Bcl2-associated athanogene 1 1.44* 
Bax Bcl2-associated X protein 1.48** 
Bcl2 B-cell leukemia/lymphoma 2 1.35* 
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Bnip3 BCL2/adenovirus E1B interacting protein 3 2.14** 
Casp12 Caspase 12 0.69 
Casp3 Caspase 3 0.67* 
Casp4 Caspase 4, apoptosis-related cysteine peptidase 1.44* 
Casp8 Caspase 8 0.62** 
Proliferation     
Ccnb2 Cyclin B2 1.61 
Ccnd1 Cyclin D1 0.51** 
Ccnd2 Cyclin D2 1.44* 
Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 1.66* 
Cks1b CDC28 protein kinase 1b 2.19** 
Rad21 RAD21 homolog (S. pombe) 0.81* 
Csf1 colony stimulating factor 1 (macrophage) 3.99*** 
Csf1r colony stimulating factor 1 receptor 0.78* 
Igf1 insulin-like growth factor 1 2.38** 
Igf1r insulin-like growth factor I receptor 0.73 
Cd34 CD34 antigen 3.48** 
Lgals3 lectin, galactose binding, soluble 3 2.01** 
METABOLISM     
mTOR signaling     
Rps6 Ribosomal protein S6 2.84*** 
Rpsa ribosomal protein SA 2.72*** 
Rps19 ribosomal protein S19 2.46*** 
Prr5l proline rich 5 like 2.39** 
Igf1 Insulin-like growth factor 1 2.38** 
Rps18 ribosomal protein S18 2.30*** 
Rps26 ribosomal protein S26 2.22*** 
Rragd Ras-related GTP binding D 2.19** 
Rps5 ribosomal protein S5 2.19*** 
Fau Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously 
expressed 
2.17*** 
Pld3 phospholipase D family. member 3 2.09*** 
Hif1a Hypoxia inducible factor 1, alpha subunit 2.06*** 
Eif3f eukaryotic translation initiation factor 3. subunit F 2.01*** 
Rps2 ribosomal protein S2 1.95** 
Rps25 ribosomal protein S25 1.92** 
Rps12 ribosomal protein S12 1.91** 
Rps16 ribosomal protein S16 1.90** 
Rps23 ribosomal protein S23 1.89** 
Rps11 ribosomal protein S11 1.82** 
Rps13 ribosomal protein S13 1.82** 
Vegfa Vascular endothelial growth factor A 1.82** 
Rps9 ribosomal protein S9 1.81*** 
Rps7 ribosomal protein S7 1.80** 
Rps15 ribosomal protein S15 1.78*** 
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Rps24 ribosomal protein S24 1.77** 
Eif3h eukaryotic translation initiation factor 3. subunit H 1.76** 
Rps27l ribosomal protein S27L 1.73** 
Eif3k eukaryotic translation initiation factor 3. subunit K 1.68** 
Rps8 ribosomal protein S8 1.66** 
Eif4ebp1 Eukaryotic translation initiation factor 4E binding protein 1 1.63** 
Rps14 ribosomal protein S14 1.62** 
Rps21 ribosomal protein S21 1.62** 
Eif3e eukaryotic translation initiation factor 3. subunit E 1.59** 
Dgkz Diacylglycerol kinase, zeta 1.58** 
Rps4x ribosomal protein S4X 1.55** 
Rps3 ribosomal protein S3 1.55** 
Rps27 ribosomal protein S27 1.53** 
Eif4b Eukaryotic translation initiation factor 4B 1.53** 
Eif4b eukaryotic translation initiation factor 4B 1.53** 
Prkaa2 Protein kinase, AMP-activated, alpha 2 catalytic subunit 1.39* 
Rragc Ras-related GTP binding C 1.35* 
Vegfb Vascular endothelial growth factor B 1.27* 
Rps6ka2 Ribosomal protein S6 kinase, polypeptide 2 1.62** 
Pik3ca Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide 0.78* 
Akt3 Thymoma viral proto-oncogene 3 0.75* 
Pik3cg Phosphoinositide-3-kinase, catalytic, gamma polypeptide 0.74** 
Rps6ka1 Ribosomal protein S6 kinase polypeptide 1 0.70** 
Rps6ka5 Ribosomal protein S6 kinase, polypeptide 5 0.70* 
Sgk1 Serum/glucocorticoid regulated kinase 1 0.66* 
Pten Phosphatase and tensin homolog 0.66* 
Ppml1 protein phosphatase. Mg2+/Mn2+ dependent. 1L 0.57** 
Pld1 Phospholipase D1 0.54** 
Prkab1 Protein kinase, AMP-activated, beta 1 non-catalytic subunit 0.53** 
Prkca Protein kinase C, alpha 0.43** 
Prkcq protein kinase C. theta 0.36*** 
Glycolysis     
Aldoa aldolase A, fructose-bisphosphate 1.98*** 
Eno1 enolase 1, (alpha) 1.86** 
Gapdh glyceraldehyde 3-phopshate dehydrogenase 1.66** 
Gpi glucose-6-phosphate isomerase 1.86** 
Pfkl phosphofructokinase, liver 1.83*** 
Pgam1 phosphoglycerate mutase 1 (brain) 2.17** 
Pgk1 phosphoglycerate kinase 1 2.10*** 
Pkm pyruvate kinase, muscle 1.81*** 
Tpi1 triosephosphate isomerase 1 2.05*** 
Mitochondria     
Atp5d ATP synthase. H+ transporting. mitochondrial F1 complex. delta 
subunit 
1.59** 
Atp5g2 ATP synthase. H+ transporting. mitochondrial Fo complex. subunit 1.65** 
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C2 (subunit 9) 
Cox4I1 cytochrome c oxidase subunit IV isoform 1 1.89*** 
Cox6a1 cytochrome c oxidase subunit VIa polypeptide 1 1.54* 
Cox6a2 cytochrome c oxidase subunit VIa polypeptide 2 8.86*** 
Cox6b1 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) 1.51** 
Cox6c cytochrome c oxidase subunit VIc 1.68** 
Cox7a2l cytochrome c oxidase subunit VIIa polypeptide 2 like 1.74** 
Cox8a cytochrome c oxidase subunit VIIIA (ubiquitous) 1.89** 
Fis1 fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) 1.55** 
Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex. 1. 7.5kDa 2.13** 
Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex. 2. 8kDa 1.61** 
Nudfb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex. 9. 22kDa 1.59** 
Psen2 presenilin 2 1.61** 
Uqcr11 ubiquinol-cytochrome c reductase. complex III subunit XI 2.18** 
Uqcrh ubiquinol-cytochrome c reductase. Complex III subunit VI 1.96*** 
Xdh xanthine dehydrogenase 4.41*** 
The fold change in expression in Mfp2
-/-
 microglia versus control is listed. *p<0.05; **p<0.01, 
***p<0.001 
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